Начало・Списък с акции・Ardelyx Inc

Ardelyx Inc

Затворен

СекторЗдравеопазване

5.01 1.01

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.88

Максимум

5.01

Ключови измерители
By Trading Economics
Приходи	-37M -38M
Продажби	-31M 94M
EPS	-0.15
Марж на печалбата	-39.805
Служители	489
EBITDA	-40M -30M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+236.77% upside

Дивиденти
By Acuity
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-219M 1.2B
Предишно отваряне	4
Предишно затваряне	5.01

Настроения в новините

By Acuity

50%

151 / 340 Класиране в Healthcare

Ardelyx Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:16 ч. UTC

Ardelyx Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

31.07.2026 г., 19:16 ч. UTC

Ardelyx Inc. shares are lower, reflecting broader market trends amid rising yields and inflationary pressures, particularly after a notable increase in crude oil prices.

30.07.2026 г., 23:51 ч. UTC

Ardelyx Inc. shares are lower in after-market trading, remaining below their 20-day moving average amid broader market weakness.

22.07.2026 г., 19:31 ч. UTC

Ardelyx Inc shares are higher in Wednesday's session, continuing a modest rise since Tuesday's close. The stock remains below its 20-day moving average.

20.07.2026 г., 19:02 ч. UTC

Ardelyx shares are lower today, reflecting broader weakness in the biotechnology sector. The stock has declined since Friday's close with no specific news identified.

Сравнение с други в отрасъла

Ценова промяна

Ardelyx Inc Прогноза

Ценова цел

By TipRanks

236.77% нагоре

12-месечна прогноза

Среден 16.67 USD 236.77%

Висок 19 USD

Нисък 15 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Ardelyx Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Ardelyx Inc през последните 3 месеца.

Настроение

By Acuity

151 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.